SIU 2017: Survival Outcomes of Younger Men (55 Years) Undergoing Radical Prostatectomy
Lisbon, Portugal (UroToday.com) While prostate cancer is typically a disease of older men, with prevalence increases with each decade of life, it can and does occur in younger men. As these men are younger, treatment options are usually more easily accessible and more options are available. However, quality of life also plays an important role.
SIU 2017: Maximal Preservation of Intra-Pelvic Urethra Using Suture-Less Technique to Improve Early Continence after Radical Prostatectomy: 15 Years Experience
Lisbon, Portugal (UroToday.com) Urinary continence after radical prostatectomy is an important quality of life indicator. As men, particularly younger men, undergo radical treatment for cancer, urinary continence is just as important for most as cancer control. As such, many attempts have been made to help improve continence outcomes.
SIU 2017: Cytoreductive and Palliative Radical Prostatectomy, Lymphadenectomy and Bilateral Orchiectomy in Advanced Prostate Cancer with Oligo-And Polymetastases
Lisbon Portugal (UroToday.com) The authors aimed to show the role of radical prostatectomy, lymphadenectomy and bilateral orchiectomy instead of androgen deprivation therapy (ADT) as an alternative treatment in patients with advanced prostate cancer with oligo-and bone poly-metastases.
SIU 2017: MP15 – 04- Polymer Delivered, Subcutaneously Administered Leuprolide Acetate Achieves Effective Testosterone Suppression below Castration Levels
Lisbon, Portugal (UroToday.com) Polymer-delivered, subcutaneous leuprolide acetate (SC-LA) has previously been shown to suppress serum testosterone (T) levels in prostate cancer patients. Luteinizing hormone-releasing hormone agonists are currently dosed independently of body weight (BW) or age. Due to the importance of achieving low T during androgen deprivation therapy, the authors attempted to understand whether patient specific factors such as age or weight may need to be taken into consideration when choosing therapy. The objective was to determine if patient weight and age correlates with the pharmacodynamic profile of SC-LA in pivotal trials of all currently available formulations (1,3,4, and 6-month doses).
SIU 2017: MP15 – 03- EMT And CD133 Expression of Circulating Tumor Cell in Predicting Prognosis and Docetaxel-Based Treatment Effect in Metastatic Castration-Resistant Pro State Cancer
Lisbon, Portugal (UroToday.com) Although circulating tumor cell (CTC) enumeration in peripheral blood has already been validated as a reliable biomarker in predicting prognosis in metastatic castration-resistant prostate cancer (mCRPC), patients with favorable CTC counts (CTC < 5/7.5 ml) still experience various survival times.
In this study, the authors attempted to explore EMT and CD133 expression of CTCs in predicting prognosis and treatment effect in mCRPC.
SIU 2017: Demystifying the Mechanistic and Functional Aspects of RNA Activation With Double-Stranded RNAs in Human Prostate Cancer Cells
Lisbon, Portugal (UroToday.com) The recently identified phenomenon of double-stranded RNA (dsRNA)-mediated gene activation (RNAa) has been studied extensively. It is present in humans, mice, and Caenorhabditis elegans, suggesting that dsRNA-mediated RNAa is an evolutionarily mechanism.
SIU 2017: Role of Growth Hormone-Releasing Hormone on Prostate Cancer
Lisbon, Portugal (UroToday.com) The involvement of growth hormone-releasing hormone (GHRH) and its receptors in several relevant processes that contribute to prostate cancer progression has been described. However, the role of such a neuropeptide on cell transformation through epithelial-mesenchymal transition (EMT) is still unknown. In this study the authors aimed to compare the expression of GHRH receptors (pCHRH-R) and their splice variants (SVs) as well as to study the carcinogenic potential of GHRH on human prostate cells.